Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Nat Commun. 2021 Feb 16;12(1):1047. doi: 10.1038/s41467-021-21383-1.
Nat Commun. 2021.
PMID: 33594075
Free PMC article.
Clinical Trial.